Research programme: chemokine receptor antagonists - Sanofi Genzyme

Drug Profile

Research programme: chemokine receptor antagonists - Sanofi Genzyme

Alternative Names: AMD 887; CXCR4 antagonists - Sanofi Genzyme

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Class
  • Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cancer; HIV infections; Rheumatoid arthritis

Most Recent Events

  • 07 Nov 2006 AnorMED has been acquired by Genzyme Corporation
  • 15 Jul 2005 This programme is still in active development
  • 01 Jun 2004 Data presented at the 17th International Conference on Antiviral Research (ICAR-2004) have been added to the Viral infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top